Description
The past few years has seen extraordinary advances in artificial intelligence (AI) in clinical medicine. More products have been cleared for clinical use, more new research-use-only applications have come to market and many more are in development. In recent years, diagnostics companies – in collaboration with AI companies – have begun implementing increasingly sophisticated machine learning techniques to improve the power of data analysis for patient care. The goal is to use developed algorithms to standardize and aid interpretation of test data by any medical professional irrespective of expertise. This way AI technology can assist pathologists, laboratorians and clinicians in complex decision-making. This report examines selected AI-based initiatives, collaborations and tests in various in vitro diagnostic (IVD) market segments.
Artificial Intelligence Markets in IVD contains the following important data points:
- The Market for AI in Diagnostics, 2019
- Forecasted Market for 2024
- Breakout of Market by Application, 2019 (Glucose, Histology, Microbiology, Hematology, Biomarker Diagnostic Aids)
- Breakout of Market by Components, 2019 (Hardware, Software, Services)
- Significant Partnerships and Initiatives in AI Related to In Vitro Diagnostics
Digital pathology products and diabetes management devices were the first to come to market with data interpretation applications. The last few years have seen the use of AI interpretation apps extended to a broader range of products including microbiology, disease genetics and cancer precision medicine. This report will review some of the AI-linked tests and test services that have come to market and others that are in development in some of the following market segments:
- Cancer Diagnostics
- Cardiac Disease Testing
- Digital Pathology
- Genetic Testing
- Glucose Monitoring
- Hematology
- Histology
- Information Technology (including Electronic Medical Records)
- Liquid Biopsy
- Microbiology
- Microbiome
- Molecular Diagnostics
- Next-Generation Sequencing
- Point of Care
- Transplant Risk Testing
- Urinalysis
Applications of AI are evolving that predict outcomes such as diagnosis, death or hospital readmission; that improve upon standard risk assessment tools; that elucidate factors that contribute to disease progression; or that advance personalized medicine by predicting a patient’s response to treatment. AI tools are in use and in development to review data and to uncover patterns in the data that can be used to improve analyses and uncover inefficiencies. Many enterprises are joining this effort. The following are among the companies and institutions whose innovations are featured in Artificial Intelligence Markets in IVD:
- Adaptive Biotechnologies
- ARUP Laboratories
- Bay Echo Labs
- BGI Genomics
- Biofourmis Singapore Pte. Ltd.
- CareDX
- Caris Life Sciences
- Case Western Reserve University
- Clever Culture Systems
- CompCyst
- Copan Diagnostics
- Curetis Group
- Diagnomics
- DNAnexus
- Eko
- Euroclone Diagnostica
- Flagship Biosciences
- Freenome
- Genomenon
- GenomeSmart
- Gilead
- Gnosis Data Analysis
- Grail
- Ibex Medical
- IBM Watson Health
- Individumed
- Inspirata
- Institut Curie
- IntegraGen
- IQVIA
- Johns Hopkins
- LabCorp
- LungLife AI
- Maxwell Plus
- Medtronic
- Nikon Instruments
- OPTiM
- Oxford Nanopore
- Paragon Genomics
- PathAI
- Pathway Genomics
- Persivia
- Phase Genomics
- Philips
- Predicine
- PredictImmune
- Predigraft
- Qiagen
- Rady Children’s Institute for Genomic Medicine
- Reliant Immune Diagnostics
- RenalytixAI
- Seegene
- Siemens Healthineers
- Sophia Genetics
- Surgisphere Corporation
- Sysmex
- UgenTec
- Viome
- Xifin
